Lurbinectedin
Zepzelca (lurbinectedin) is a small molecule pharmaceutical. Lurbinectedin was first approved as Zepzelca on 2020-06-15. It is used to treat small cell lung carcinoma in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| respiratory tract diseases | D012140 |
Trade Name
FDA
EMA
Zepzelca
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lurbinectedin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZEPZELCA | Jazz Pharmaceuticals | N-213702 RX | 2020-06-15 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| zepzelca | New Drug Application | 2025-10-02 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| small cell lung carcinoma | — | D055752 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
LURBINECTEDIN, ZEPZELCA, JAZZ | |||
| 2027-06-15 | ODE-304 | ||
| 2025-06-15 | NCE | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Lurbinectedin, Zepzelca, Jazz | |||
| 7763615 | 2029-12-13 | DS, DP | U-2836 |
HCPCS
Code | Description |
|---|---|
| J9223 | Injection, lurbinectedin, 0.1 mg |
Clinical
Clinical Trials
61 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Small cell lung carcinoma | D055752 | — | — | 9 | 13 | 8 | — | 3 | 27 |
| Neoplasms | D009369 | — | C80 | 11 | 8 | 1 | — | — | 17 |
| Lung neoplasms | D008175 | — | C34.90 | 2 | 3 | 2 | — | 2 | 9 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 3 | 1 | 1 | — | — | 4 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 1 | 1 | 1 | — | — | 2 |
| Leiomyosarcoma | D007890 | — | — | 1 | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | — | — | 7 | 8 | — | — | — | 8 |
| Small cell carcinoma | D018288 | — | — | 3 | 5 | — | — | — | 6 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 2 | — | — | — | 4 |
| Carcinoma | D002277 | — | C80.0 | 2 | 4 | — | — | — | 4 |
| Non-small-cell lung carcinoma | D002289 | — | — | 1 | 2 | — | — | — | 3 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 3 | 3 | — | — | — | 3 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 2 | 2 | — | — | — | 3 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | 3 | 3 | — | — | — | 3 |
| Colorectal neoplasms | D015179 | — | — | 2 | 1 | — | — | — | 2 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 1 | — | — | — | 2 |
Show 11 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Head and neck neoplasms | D006258 | — | — | 1 | — | — | — | — | 1 |
| Female genital neoplasms | D005833 | — | — | 1 | — | — | — | — | 1 |
| Endometrioid carcinoma | D018269 | — | — | 1 | — | — | — | — | 1 |
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Preleukemia | D011289 | — | — | 1 | — | — | — | — | 1 |
| Acute disease | D000208 | — | — | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lurbinectedin |
| INN | lurbinectedin |
| Description | Lurbinectedin, sold under the brand name Zepzelca, is a medication used for the treatment of small cell lung cancer.
|
| Classification | Small molecule |
| Drug class | ecteinascidin derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc2[nH]c3c(c2c1)CCN[C@]31CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H](O)[C@@H]3Cc5cc(C)c(OC)c(O)c5[C@H]([C@H]21)N3C)OCO4 |
Identifiers
| PDB | — |
| CAS-ID | 497871-47-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4297516 |
| ChEBI ID | — |
| PubChem CID | 57327016 |
| DrugBank | DB12674 |
| UNII ID | 2CN60TN6ZS (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Zepzelca – Jazz Pharmaceuticals
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 937 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
990 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use